School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Avalyn Pharma Inc AVLN

Healthcare · Pharmaceuticals

$25.76last close 2026-10-09 · market cap $1.14B · delayed data

Trailing returns

1M-28.21%
3M-10.93%

Basis: Adjusted daily closes.

What it does

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis.

Open AVLN in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies